Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Benzinga Newsdesk www.benzinga.com Negative 64.0%

Neg 64% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.